InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Snodgres Jon, Chief Financial Officer. Insider active across 2 companies, notably Repligen CORP. Aggregated, 15 disclosures have been recorded. Split: 0 buy · 4 sells. Total volume traded: €1.6m. Activity tracked since 14 May 2021. The latest transaction was filed on 16 May 2023 (Retenue fiscale). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
710 shares@ US$154.034.9% of flowCommon StockSEC:0000950170-23-022579:0
4,848 shares0Common StockSEC:0000899243-23-007201:0
521 shares@ US$173.284.1% of flowCommon StockSEC:0000899243-23-006613:0
682 shares@ US$173.445.4% of flowCommon StockSEC:0000899243-23-006511:0
5,647 shares@ US$200.0051.1% of flowCommon StockSEC:0000899243-23-005490:0
466 shares@ US$59.521.4% of flowCommon StockSEC:0000899243-22-033400:0
3,047 shares@ US$86.1012.5% of flowCommon StockSEC:0000899243-22-028997:0
2,000 shares@ US$220.0020.7% of flowCommon StockSEC:0000899243-22-027415:0
712 shares@ US$150.400.0018% mcap22.8% of flowCommon StockSEC:0000899243-22-018416:0
2,952 shares@ US$33.870.0016% mcap20.4% of flowCommon StockSEC:0000899243-22-010327:0
695 shares@ US$196.700.0021% mcap27.0% of flowCommon StockSEC:0000899243-22-008752:0
3,443 shares0Common StockSEC:0000899243-22-008178:0
900 shares0Common StockSEC:0000899243-22-007255:0
470 shares@ US$172.6014.9% of flowCommon StockSEC:0000899243-21-019720
470 shares@ US$172.600.0012% mcap14.9% of flowCommon StockSEC:0000899243-21-019720:0
15 of 15 declarations
About Snodgres Jon
Jon Snodgres serves as the Chief Financial Officer at REPLIGEN CORP. He is responsible for overseeing the financial operations of the company, including financial planning, budget management, and financial reporting. His expertise in finance and strategy is crucial for supporting REPLIGEN's growth and ensuring effective management of financial resources.
